Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538699 | 0.91 | CHRM3 (0.63) | CHRM3ADRB2 | |
| SCHEMBL3563984 | 0.89 | CHRM3 (0.53) | CHRM3ADRB2 | |
| SCHEMBL3557723 | 0.88 | CHRM3 (0.56) | CHRM3ADRB2 | |
| SCHEMBL3534654 | 0.87 | CHRM3 (0.62) | CHRM3ADRB2 | |
| SCHEMBL3566548 | 0.87 | CHRM3 (0.57) | CHRM3ADRB2 | |
| SCHEMBL3570391 | 0.87 | CHRM3 (0.57) | CHRM3ADRB2 | |
| SCHEMBL3559488 | 0.86 | CHRM3 (0.61) | CHRM3ADRB2 | |
| SCHEMBL643127 | 0.85 | CHRM3 (0.56) | CHRM3ADRB2 | |
| SCHEMBL4691610 | 0.85 | CHRM3 (0.67) | CHRM3 | |
| SCHEMBL644474 | 0.85 | CHRM3 (0.63) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456199-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | claimed |
| US-20050203139-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | claimed |
| US-7858795-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090048299-A1 | or anticholinergic agents such as biphenyl-2-ylcarbamic acid 1-[2-({6-[(4-hydroxybenzylamino)methyl]pyridin-2-ylmethyl}carbamoyl)ethyl]piperidin-4-yl ester, used for the treatment of respiratory system disorders such as chronic obstructive pulmonary disease and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-02-19 | — | — | US | disclosed |
| US-7456199-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20050203139-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048299-A1 | or anticholinergic agents such as biphenyl-2-ylcarbamic acid 1-[2-({6-[(4-hydroxybenzylamino)methyl]pyridin-2-ylmethyl}carbamoyl)ethyl]piperidin-4-yl ester, used for the treatment of respiratory system disorders such as chronic obstructive pulmonary disease and asthma | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885ADRB2 16/4885 |
| US-20050203139-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885ADRB2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.